ResMed (NYSE:RMD) hit a new 52-week high Wednesday as it is currently trading at $49.09, above its previous 52-week high of $48.47 with 17,074 shares traded as of 9:35 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- ResMed (NYSE: RMD) hit a new 52-week high Wednesday as it is currently trading at $49.09, above its previous 52-week high of $48.47 with 17,074 shares traded as of 9:35 a.m. ET. Average volume has been 1.1 million shares over the past 30 days. ResMed has a market cap of $6.77 billion and is part of the health care sector and health services industry. Shares are up 15% year to date as of the close of trading on Tuesday. ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The company has a P/E ratio of 22.3, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full ResMed Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.